It has also been shown that activated T cells can be supported by transgenic expression of IL-2 in vivo[7], [8] and IL-2 has already been approved for clinical use in patients with metastatic renal-cell carcinoma and malignant melanoma [5]. This evidence concerns the gene IL2 and melanoma.